A
Akira Inoue
Researcher at Tohoku University
Publications - 273
Citations - 14091
Akira Inoue is an academic researcher from Tohoku University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 40, co-authored 242 publications receiving 12528 citations. Previous affiliations of Akira Inoue include Nippon Medical School.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto,Katsuyuki Kiura,Makoto Nishio,Kazuhiko Nakagawa,Makoto Maemondo,Akira Inoue,Toyoaki Hida,Nobuyuki Yamamoto,Hiroshige Yoshioka,Masao Harada,Yuichiro Ohe,Naoyuki Nogami,Kengo Takeuchi,Tadashi Shimada,Tomohiro Tanaka,Tomohide Tamura +15 more
TL;DR: CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC, and the study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.
Journal ArticleDOI
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Akira Inoue,Takuji Suzuki,Tatsuro Fukuhara,Makoto Maemondo,Yuichiro Kimura,Naoto Morikawa,Hiroshi Watanabe,Yasuo Saijo,Toshihiro Nukiwa +8 more
TL;DR: Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity, and a subsequent randomized trial comparing gefITinib with standard chemotherapy is warranted.
Journal ArticleDOI
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki,Jasmine Foo,Geoffrey R. Oxnard,Katherine E. Hutchinson,Kadoaki Ohashi,Romel Somwar,Lu Wang,Katherine R. Amato,Maria E. Arcila,Martin L. Sos,Nicholas D. Socci,Agnes Viale,Elisa de Stanchina,Michelle S. Ginsberg,Roman K. Thomas,Mark G. Kris,Akira Inoue,Marc Ladanyi,Vincent A. Miller,Franziska Michor,William Pao +20 more
TL;DR: Predictive models of EGFR-mutant tumor behavior point to alternative drug dosing strategies to prevent and treat acquired resistance, and individual models based on the characteristics of diverse cancer cell types could offer clues for designing optimal treatment strategies.
Journal ArticleDOI
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Akira Inoue,Kazuhiko Kobayashi,Makoto Maemondo,Shunichi Sugawara,Satoshi Oizumi,Hiroaki Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,H. Hirano,Kozo Yoshimori,Toshiyuki Harada,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +18 more
TL;DR: Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended.